Four Mile Relay Team, UM Track, 1907 Penn Relays Champions

[L-R: James W. Maloney Horace Ramey Harry Coe, Floyd Rowe]

Four Mile Relay Team, UM Track, 1906 Penn Relays Champions

[L-R: James W. Maloney Horace Ramey Harry Coe, Floyd Rowe]

Four Mile relay Team, UM Track, 1905 Penn Relays Champions

[L-R: Irving Stone, Harry Coe, Floyd Rowe Horace Ramey ]

An appeal to the public, in compliance with the mandate of the ref. G.C. Smith, of Penzance.

Mode of access: Internet.

The plays,

Mode of access: Internet.

The dramatic works of William Shakespeare, from the text of Johnson, Stevens, and Reed;

Mode of access: Internet.

The dramatic works of William Shakspeare, from the text of Johnson, Stevens, and Reed; with glossarial notes, his life, and a critique on his genius & writings

Title vignette.

The dramatic works of Shakspeare [sic].

Full-bound in brown calf; blind-tooled borders and gilt-stamped rulings on covers; inner gilt-dentelles, marbled endpapers; gilt-stamped lettering on black panels and gilt-stamped designs between raised bands on spine; marbled edges.

Herbarts Ansichten von dem Zwecke des lateinischen und griechischen Unterrichtes dargestellt und beurtheilt.

Thesis (doctoral)--Universitat Jena.

Functional activities of the pancreas and liver;

Mode of access: Internet.

Theory and practice of crown and bridge prosthesis ...

"History of fixed partial prostheses, by Claude Rowe Baker": p. 1-14.

Fiji and the Fijians /

pt.1. The islands and their inhabitants [by Thomas Williams]--pt.2. Mission history [by James Calvert]

Great and Little Miami River Basins /

Mode of access: Internet.

Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation

The granulocyte colony-stimulating factor (G-CSF) and Fit-3 receptor agonist progenipoietin-1 (ProGP-1) has potent effects on dendritic cell (DC) expansion and may be an alternative to G-CSF for the mobilization of stem cells for allogeneic stem cell transplantation (SCT). We studied the ability of stem cell grafts mobilized with this agent to induce graft-versus-host disease (GVHD) to minor and major histocompatibility antigens in the well-described B6 --> B6D2F1 SCT model. ProGP-1, G-CSIF, or control diluent was administered to donor B6 mice. ProGP-1 expanded all cell lineages in the spleen, and unseparated splenocytes from these animals produced large amounts of interleukin 10 (IL-10) and transforming growth factor beta (TGFbeta) whereas the expression of T-cell adhesion molecules was diminished. Transplantation survival was 0%, 50%, and 90% in recipients of control-, G-CSF-, and ProGP-1-treated allogeneic donor splenocytes, respectively (P < .0001). Donor pretreatment with ProGP-1 allowed a 4-fold escalation in T-cell dose over that possible with G-CSF. Donor CD4 T cells from allogeneic SCT recipients of ProGP-1 splenocytes demonstrated an anergic response to host antigen, and cytokine production (interferon gamma [IFNγ], IL-4, and IL-10) was also reduced while CD8 T-cell cytotoxicity to host antigens remained intact. Neither CD11c(hi) DCs nor CD11c(dim)/B220(hi) DCs from ProGP-1-treated animals conferred protection from GVHD when added to control spleen. Conversely, when equal numbers of purified T cells from control-, G-CSF-, or ProGP-1-treated allogeneic donors were added to allogeneic T-cell-depleted control spleen, survival at day 60 was 0%, 15%, and 90%, respectively (P < .0001). The improved survival in recipients of ProGP-1 T cells was associated with reductions in systemic tumor necrosis factor alpha generation and GVHD of the gastrointestinal tract. We conclude that donor pretreatment with ProGP-1 is superior to G-CSIF for the prevention of GVHD after allogeneic SCT, primarily due to incremental affects on T-cell phenotype and function